Compare Abeona Therapeutics Inc (ABEO) vs iShares MSCI Indonesia ETF (EIDO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares MSCI Indonesia ETF — how do they compare? Abeona Therapeutics Inc trades at $6.7 (market cap $373.32M), while iShares MSCI Indonesia ETF trades at $11.7. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | EIDO | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $19.22 |
52-Week Low | $4.17 | $10.80 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
EIDO (iShares MSCI Indonesia ETF) trades at $11.81, up 3.14% today, but technical indicators show a bearish trend with selling pressure outweighing buying signals. The ETF faces headwinds from Indonesia's monetary policy tightening and dividend reductions, with key financial ratios currently unavailable for fundamental assessment. Recent news highlights Indonesia's economic initiatives including AI integration in government programs and reforestation efforts.
The outlook remains cautious as Bank Indonesia's rate hikes to defend the rupiah create currency volatility risks. While long-term GDP growth potential exists through government initiatives, near-term pressures from dividend cuts and technical bearishness suggest careful monitoring of Indonesian economic stability and ETF performance metrics is warranted for investors seeking emerging market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →
